A review of Judah Folkman's remarkable achievements in biomedicine.
作者信息
Cao Yihai, Langer Robert
机构信息
Department of Microbiology and Tumor and Cell Biology, Karolinska Institute, 171 77 Stockholm, Sweden.
出版信息
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13203-5. doi: 10.1073/pnas.0806582105. Epub 2008 Sep 4.
Abstract
摘要
相似文献
1
A review of Judah Folkman's remarkable achievements in biomedicine.对犹大·福克曼在生物医学领域卓越成就的回顾。
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13203-5. doi: 10.1073/pnas.0806582105. Epub 2008 Sep 4.
2
Judah Folkman.犹大·福克曼
Thromb Haemost. 2008 Feb;99(2):250.
3
Judah Folkman's contribution to the inhibition of angiogenesis.朱达·福克曼对血管生成抑制的贡献。
Lymphat Res Biol. 2008;6(3-4):203-7. doi: 10.1089/lrb.2008.1016.
4
Retrospective: Judah Folkman (1933-2008).回顾：朱达·福克曼（1933 - 2008）。
Science. 2008 Feb 22;319(5866):1055. doi: 10.1126/science.1156080.
5
Judah Folkman.犹大·福克曼
Semin Ophthalmol. 2009 May-Jun;24(3):128-9. doi: 10.1080/08820530902800116.
6
Angiogenesis and the progress of vascular and tumor biology: a tribute to Judah Folkman.血管生成与血管及肿瘤生物学的进展：向朱达·福克曼致敬。
Thromb Haemost. 2008 Apr;99(4):647-50. doi: 10.1160/TH08-02-0096.
7
Judah Folkman leaves expanding legacy.犹大·福克曼留下了不断扩展的遗产。
J Natl Cancer Inst. 2008 Mar 19;100(6):380-1. doi: 10.1093/jnci/djn072. Epub 2008 Mar 11.
8
Judah Folkman, a pioneer in the study of angiogenesis.朱达·福克曼，血管生成研究领域的先驱。
Angiogenesis. 2008;11(1):3-10. doi: 10.1007/s10456-008-9092-6. Epub 2008 Feb 5.
9
Judah Folkman, MD, 1933-2008.朱达·福克曼医学博士，1933年 - 2008年。
Pharos Alpha Omega Alpha Honor Med Soc. 2009 Winter:4-8.
10
The scientific contributions of M. Judah Folkman to cancer research.朱达·福克曼对癌症研究的科学贡献。
Nat Rev Cancer. 2008 Aug;8(8):647-54. doi: 10.1038/nrc2458. Epub 2008 Jul 17.
引用本文的文献
1
Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives.结直肠癌的血管靶向治疗：当前策略与未来展望
Cancers (Basel). 2024 Feb 22;16(5):890. doi: 10.3390/cancers16050890.
2
An In Vivo Dual-Observation Method to Monitor Tumor Mass and Tumor-Surface Blood Vessels for Developing Anti-Angiogenesis Agents against Submillimeter Tumors.一种用于监测毫米级肿瘤的肿瘤质量和肿瘤表面血管的体内双观察方法，用于开发抗血管生成药物。
Int J Mol Sci. 2023 Dec 7;24(24):17234. doi: 10.3390/ijms242417234.
3
The neural addiction of cancer.癌症的神经成瘾性。
Nat Rev Cancer. 2023 May;23(5):317-334. doi: 10.1038/s41568-023-00556-8. Epub 2023 Apr 11.
4
The thirst for learning: Judah Folkman, MD.求知若渴：医学博士朱达·福克曼
Pediatr Radiol. 2023 Mar;53(3):571-573. doi: 10.1007/s00247-022-05555-9. Epub 2022 Dec 3.
5
Angiogenesis in Lymph Nodes Is a Critical Regulator of Immune Response and Lymphoma Growth.淋巴结中的血管生成是免疫反应和淋巴瘤生长的关键调节因子。
Front Immunol. 2020 Dec 3;11:591741. doi: 10.3389/fimmu.2020.591741. eCollection 2020.
6
Current Concepts in Multi-Modality Imaging of Solid Tumor Angiogenesis.实体肿瘤血管生成的多模态成像的当前概念
Cancers (Basel). 2020 Nov 3;12(11):3239. doi: 10.3390/cancers12113239.
7
Potential Therapeutic Strategies for Lung and Breast Cancers through Understanding the Anti-Angiogenesis Resistance Mechanisms.通过了解抗血管生成耐药机制为肺癌和乳腺癌提供潜在的治疗策略。
Int J Mol Sci. 2020 Jan 15;21(2):565. doi: 10.3390/ijms21020565.
8
Placental mesenchymal stromal cells as an alternative tool for therapeutic angiogenesis.胎盘间充质基质细胞作为治疗性血管生成的一种替代工具。
Cell Mol Life Sci. 2020 Jan;77(2):253-265. doi: 10.1007/s00018-019-03268-1. Epub 2019 Aug 29.
9
Fibronectin Regulation of Integrin B1 and SLUG in Circulating Tumor Cells.纤连蛋白对循环肿瘤细胞中整合素 B1 和 SLUG 的调节作用。
Cells. 2019 Jun 20;8(6):618. doi: 10.3390/cells8060618.
10
Molecular biomarker-guided anti-angiogenic targeted therapy for malignant glioma.分子生物标志物指导的抗血管生成靶向治疗恶性胶质瘤。
J Cell Mol Med. 2019 Aug;23(8):4876-4882. doi: 10.1111/jcmm.14417. Epub 2019 Jun 18.
本文引用的文献
1
Obituary: M. Judah Folkman (1933-2008).讣告：M. 朱达·福克曼（1933 - 2008）
Nature. 2008 Feb 14;451(7180):781. doi: 10.1038/451781a.
2
Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released.血管生成受一种新机制调控：促血管生成蛋白和抗血管生成蛋白被分别组织在血小板α颗粒中，并以不同方式释放。
Blood. 2008 Feb 1;111(3):1227-33. doi: 10.1182/blood-2007-09-113837. Epub 2007 Oct 25.
3
Angiogenesis: an organizing principle for drug discovery?血管生成：药物发现的一个组织原则？
Nat Rev Drug Discov. 2007 Apr;6(4):273-86. doi: 10.1038/nrd2115.
4
Ranibizumab for neovascular age-related macular degeneration.雷珠单抗用于治疗新生血管性年龄相关性黄斑变性。
N Engl J Med. 2006 Oct 5;355(14):1419-31. doi: 10.1056/NEJMoa054481.
5
Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis.人类脂肪肉瘤的长期休眠与肿瘤血管生成受损有关。
FASEB J. 2006 May;20(7):947-9. doi: 10.1096/fj.05-3946fje. Epub 2006 Apr 25.
6
Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model.短合成内皮抑素肽在体外抑制内皮细胞迁移，并在小鼠模型中抑制子宫内膜异位症。
Fertil Steril. 2006 Jan;85(1):71-7. doi: 10.1016/j.fertnstert.2005.07.1290.
7
Angiogenesis in life, disease and medicine.生命、疾病与医学中的血管生成
Nature. 2005 Dec 15;438(7070):932-6. doi: 10.1038/nature04478.
8
A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer.抗血管生成（节拍式）化疗在复发或进展性儿科癌症患者中的可行性试验。
J Pediatr Hematol Oncol. 2005 Nov;27(11):573-81. doi: 10.1097/01.mph.0000183863.10792.d4.
9
Cancer without disease.无疾病的癌症。
Nature. 2004 Feb 26;427(6977):787. doi: 10.1038/427787a.
10
Antiangiogenic scheduling of lower dose cancer chemotherapy.低剂量癌症化疗的抗血管生成给药方案
Cancer J. 2001 Sep-Oct;7(5):427-36.
Zotero 插件